2025年第四季度业绩要点 · 第四季度营收总额为 197亿美元，增长12%，按固定汇率计算增长9% - 软件业务营收增长14%，按固定汇率计算增长11% 北京，2026年1月29日——今天，IBM（NYSE: IBM）发布了2025年第四季度业绩报告。 IBM董事长兼首席执行官 Arvind Krishna 表示："在第四季度，我们延续了强劲的营收增长，其中软件 业务表现突出，实现双位数增长。此外，得益于新一代主机平台的广泛采用，基础设施业务继续保持双 位数营收增长。目前，我们的生成式人工智能（generative AI）业务规模已突破125亿美元。这些成就为 IBM的2025年画上了圆满句号，公司在营收、利润和自由现金流方面的表现均超预期。进入2026年，我 们势头强劲、优势显著，这也让我们对全年业绩充满信心——预计按固定汇率计算的营收增长将超 5%，自由现金流将实现同比约10亿美元的增长。" - 咨询业务营收增长3%，按固定汇率计算增长1% - 基础设施业务营收增长21%，按固定汇率计算增长17% · 利润率：按照美国通用会计准则（GAAP）计算的毛利率为 60.6%，增长110个基点；按非美国通用会 ...

Core Viewpoint - Novartis has emerged as a pioneer in the field of targeted radioligand therapy, demonstrating significant clinical results in cancer treatment [2][3] Group 1: Clinical Results and Innovations - Initial clinical trials of Novartis' radioligand therapy showed that approximately 9% of participants had complete cancer cell disappearance, which increased to 21% in subsequent trials [3] - The therapy involves intravenous administration of a solution containing radioactive isotopes attached to ligands that specifically target cancer cell receptors, allowing for precise delivery of radiation [5] - Lutathera, a radioligand therapy drug acquired by Novartis, was first approved in 2017 for certain gastrointestinal cancers, and Pluvicto, a prostate cancer drug, received approval in 2022 with expanded indications [8][14] Group 2: Market Potential - The market for radioligand therapy is estimated to reach $10 billion, with potential growth to $25-30 billion if the therapy meets expectations [8][11] - Novartis is exploring various isotopes and therapy combinations, aiming to expand indications to other cancer types such as lung, breast, pancreatic, and colon cancers [9][11] Group 3: Challenges and Logistics - The production and delivery of radioligand therapy face significant logistical challenges, including the need for rapid production and transportation of radioactive materials to patients within a limited time frame [12][15] - Novartis has been investing in overcoming these challenges, including the use of generative AI to predict logistics issues and the establishment of additional production facilities in China, Japan, and the U.S. [14][16] - The therapy requires specialized facilities for patient isolation due to the retention of radioactive materials in the body, which poses additional infrastructure challenges [15][16] Group 4: Competitive Landscape - Other pharmaceutical companies, including Eli Lilly, AstraZeneca, and Sanofi, are also pursuing opportunities in the radioligand therapy space, indicating a growing competitive market [9] - Novartis has a first-mover advantage with seven potential radioligand therapies in clinical trials and a strong pipeline, setting a high entry barrier for competitors [9][16]

Core Viewpoint - The article discusses advancements in prime editing (PE) technology, particularly focusing on the development of MLH1 small binders (MLH1-SB) using AI tools to enhance editing efficiency in genome editing applications [2][4]. Group 1: Prime Editing Technology - Prime editing is a novel genome editing technique that allows for precise modifications, including base substitutions and small insertions or deletions [2]. - The efficiency of prime editing is often limited by the mismatch repair (MMR) pathway, which can hinder the integration of desired edits at target sites [6][7]. Group 2: AI-Driven Innovations - The research utilized the AI protein design tool RFdiffusion to create MLH1 small binders that inhibit MMR activity, thereby improving prime editing efficiency [3][9]. - AlphaFold3 was employed to efficiently screen the designed proteins, leading to the identification of an optimal MLH1-SB composed of only 82 amino acids, which integrates well with existing PE architectures [10][11]. Group 3: Efficiency Improvements - The newly developed PE-SB platforms, such as PEmax-SB, PE6-SB, and PE7-SB, demonstrated significant improvements in editing efficiency, with PE7-SB2 showing an increase of approximately 18.8 times compared to PEmax and 2.5 times compared to PE7 in human cells [11]. - In vivo studies indicated that PE7-SB2's efficiency was about 3.4 times greater than that of PE7 in mouse models [11]. Group 4: Implications for Gene Therapy - The compact size of the MLH1-SB allows for easier integration and delivery in gene therapy applications, which is crucial for effective in vivo gene editing [11]. - The advancements in AI-driven protein design are expected to facilitate the development of efficient gene editing therapies, potentially transforming the landscape of genetic medicine [15].